Literature DB >> 10381796

Characterization of 2-[125I]iodomelatonin binding sites in Syrian hamster peripheral organs.

P Paul1, C Lahaye, P Delagrange, J P Nicolas, E Canet, J A Boutin.   

Abstract

The neurohormone melatonin is a key agent in synchronizing the circadian rhythms. At least three types of binding sites have been described for melatonin: the G-coupled, seven-transmembrane domain receptors mt1 and MT2 and a putative binding site called MT3. The latter has been described in hamster brain membranes, and its binding capacity is optimum at 4 degrees C. We further characterized this binding site on other peripheral hamster tissues, including intestine, liver, kidney, lung, muscle, and heart. We found a high level of binding sites (>30 fmol/mg of protein) in intestine and kidney. Furthermore, we completed the existing pharmacological profile of this site, which can now be described as 2-iodomelatonin > 6-chloromelatonin > methy-isobutyl-amiloride > acridine orange > 5-methylcarbonylamino-N-acetyltryptamine > prazosin > N-acetylserotonin > melatonin. This profile was found in all the hamster organs tested that had a large number of binding sites, namely, brain, intestine, kidney and liver. Furthermore, when comparisons were possible, the MT3 pharmacological characteristics were similar to those described in the literature for hamster brain and testis. This profile was compared to the pharmacology obtained on human cloned mt1 and MT2 receptors and proved to be completely different, as expected. We provide new evidence for an alternate melatonin binding site not only in hamster brain but also in some peripheral organs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10381796

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

Review 1.  Melatonin membrane receptors in peripheral tissues: distribution and functions.

Authors:  Radomir M Slominski; Russel J Reiter; Natalia Schlabritz-Loutsevitch; Rennolds S Ostrom; Andrzej T Slominski
Journal:  Mol Cell Endocrinol       Date:  2012-01-08       Impact factor: 4.102

Review 2.  Hepatoprotective actions of melatonin: possible mediation by melatonin receptors.

Authors:  Alexander M Mathes
Journal:  World J Gastroenterol       Date:  2010-12-28       Impact factor: 5.742

3.  Melatonin inhibits tachykinin NK₂ receptor-triggered 5-HT release from guinea pig isolated colonic mucosa.

Authors:  Shu-ichi Kojima; Atsushi Tohei; Masashi Ikeda
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

4.  Nose-to-brain transport of melatonin from polymer gel suspensions: a microdialysis study in rats.

Authors:  R Jayachandra Babu; Pankaj Patrick Dayal; Kasturi Pawar; Mandip Singh
Journal:  J Drug Target       Date:  2011-03-23       Impact factor: 5.121

5.  X-ray structural studies of quinone reductase 2 nanomolar range inhibitors.

Authors:  Scott D Pegan; Megan Sturdy; Gilles Ferry; Philippe Delagrange; Jean A Boutin; Andrew D Mesecar
Journal:  Protein Sci       Date:  2011-05-23       Impact factor: 6.725

6.  Melatonin Binding to Human NQO2 by Isothermal Titration Calorimetry.

Authors:  Barbara Calamini; Gilles Ferry; Jean A Boutin
Journal:  Methods Mol Biol       Date:  2022

7.  Measuring Binding at the Putative Melatonin Receptor MT3.

Authors:  Céline Legros; Philippe Dupuis; Gilles Ferry; Jean A Boutin
Journal:  Methods Mol Biol       Date:  2022

8.  Ocular hypotensive effects of melatonin receptor agonists in the rabbit: further evidence for an MT3 receptor.

Authors:  Jesus Pintor; Teresa Peláez; Charles H V Hoyle; Assumpta Peral
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

Review 9.  Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new?

Authors:  R Jockers; P Maurice; J A Boutin; P Delagrange
Journal:  Br J Pharmacol       Date:  2008-05-19       Impact factor: 8.739

Review 10.  Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.

Authors:  Masaomi Miyamoto
Journal:  CNS Neurosci Ther       Date:  2009       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.